Find out more about the availability of cancer medicines in
- Enter in the search engine or select from the list
Select the type of cancer and see a full compilation of pharmaceutical therapies authorized by European Medicines Agency (EMA) in last 15 years and recommended by the European Society for Medical Oncology (or enter the medicine and check if it is reimbursed).
- Download or print out the list
Medicines increasing the chances of your successful recovery might be on the list.
- Consult the list with your doctor
Ask your doctor to verify the possible medicines and indicate the once which can be the most effective in your case. The list may also include non-reimbursed therapies. In such a situation contact us - we will help you find a solution.
Hodgkin’s disease
How to read the list?Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.
-
PembrolizumabPembrolizumab as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.No reimbursementThe drug in this indication is not refundedESMOSubstance is recommended by ESMO.
-
Brentuximab vedotinBrentuximab Vedotin is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). Brentuximab Vedotin is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT). Brentuximab Vedotin is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following ASCT, or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.Reimbursement with restrictionsThe drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
NivolumabNivolumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.